USD 24667.82 million
Lung Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy (Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib), By Cancer Type(Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC)), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35J2088 |
Region:
Global |
Published Date: September, 2024
Pages:
242
|Tables:
122
|Figures:
77
Lung Cancer Therapeutics Market Insights
Global Lung Cancer Therapeutics Market size was valued at around USD 32.2 billion in 2022 and is expected to rise from USD 36.4 billion in 2023 to reach a value of USD 86.8 billion by 2031, at a CAGR of 13.2% over the forecast period (2024–2031).
In 2021, there will be close to 15 million cancer deaths, accounting for 1 in 8 fatalities worldwide. In 2021, 21.5 million cancer cases were reported. The necessity for various treatment modalities and medications to treat the illness is increased with the rise in cancer cases around the world, particularly by the enormous prevalence of lung cancers. The lung cancer market is predicted to increase quickly due to extensive investment and the development of effective treatment options. An increasing number of individuals undergoing lung cancer surgery and treatment may be advantageous for the global industry as well.
Surgical intervention, imaging-based diagnostics, and pharmaceutical support can all be used in the treatment of lung cancer. Government and insurance companies spend a lot on these parts, but patients typically foot the bill for the extra expenses. Given the high costs of treating lung cancer, both governments around the world and cancer patients are under a significant financial strain. Due to these high prices, fewer patients choose surgical operations as a form of treatment, which may significantly impede business growth.
The COVID-19 pandemic has caused a number of significant delays in the detection, diagnosis, and treatment processes, which have been consistently noted across all types of cancer in the UK. Pre-COVID, it was becoming more and more clear that cancer was the leading cause of death worldwide. Lung cancer alone kills about 35,000 people annually, which is more than are lost to breast and bowel cancers combined. Experts anticipate an additional 1372 lung cancer deaths five years after the discovery of COVID-19 due to a significant rise in the late-stage appearance of the disease. The acuteness of COVID-19 is elevated in patients with lung cancer, with determinants being more patient-specific, such as smoking status and chronic obstructive pulmonary disease (COPD), than tumor-specific traits or treatments.
US Lung Cancer Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.
Market Snapshot - 2024–2031
Global Market Size
Largest Segment
Biologics
Fastest Growth
Biologics
Growth Rate
10.41% CAGR
Global Lung Cancer Therapeutics Market 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)
To get more reports on the above market click here to Buy The Report
Lung Cancer Therapeutics Market Segmental Analysis
Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Distribution Channel, and region. Based on Therapy, the market is segmented into Targeted Therapy (Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib, Others), Immunotherapy (Durvalumab, Nivolumab, Atezolizumab, Pembrolizumab), Chemotherapy. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC). Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Lung Cancer Therapeutics Market Analysis by Cancer Type
Small cell lung cancer, non-small cell lung cancer, and lung carcinoid cancer are all included in the type segment. The non-small cell lung cancer category is the most common type employed in the market for lung cancer therapies. Non-small cell lung cancer is the most common kind, accounting for around 85% of lung cancer cases. The growth of non-small cell lung cancer is slow. Depending on the patient's age and underlying circumstances, advanced treatments are used to treat non-small cell lung cancer.
Lung Cancer Therapeutics Market Analysis by Therapy
Radiotherapy, chemotherapy, targeted therapy, and immunotherapy are all included in the therapy category. Tarceva, Gilotrif, Iressa, Avastin, and other medications are also included in the targeted therapy section. Internal radiotherapy, external beam radiotherapy, and systematic radiotherapy are also included in the radiotherapy segment. The chemotherapy section also contains Taxotere, Navelbine, Alimta, Gemzar, and other drugs. The market for lung cancer therapies uses the targeted therapy category the most frequently of these. The most recent treatment for lung cancer that has been found to reduce the impact of radiation on organs other than the lungs is called targeted therapy. Target therapy is superior to other therapies, according to numerous research.
Lung Cancer Therapeutics Market Aalysis by Molecule
Small molecules and biologics are included in the molecular type segment. The market for lung cancer therapies is dominated by the small molecules category. Because specialists are increasingly favouring monotherapy, small molecules are being employed more frequently in the treatment of lung cancer. Small molecules are simpler to absorb and dissolve in formulations, which is advantageous for the creation of medications that will treat lung cancer.
Lung Cancer Therapeutics Market Analysis by End Use
Hospitals, diagnostic facilities, specialist clinics, and others are included in the end-user segment. Due to the high patient volume, hospitals use lung cancer therapies the most. Lung cancer is completely diagnosed and treated at hospitals, requiring the use of tools and medications.
Global Lung Cancer Therapeutics Market Share By Molecule, 2021 (%)
To get detailed analysis on other segments, Request For Free Sample Report
Lung Cancer Therapeutics Market Regional Insights
The lung cancer treatments and diagnostics market was dominated by North America in 2021, accounting for 39.17% of global value. The large percentage of elderly people in the region, the presence of numerous international and local manufacturers, and investments made to diagnose cancer at an earlier stage are only a few of the reasons for the market's expansion. However, throughout the predicted period of 2022–2028, Asia–Pacific is expected to have faster development. The region is making significant investments in radiology treatments and chemotherapies. China and Japan are prepared to raise their spending on cutting-edge immunotherapies.
Global Lung Cancer Therapeutics Market By Geography, 2021 - 2028
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Lung Cancer Therapeutics Market Dynamics
Lung Cancer Therapeutics Market Driver
- The rise in chronic tobacco use is to blame for the rise in lung cancer cases, which now account for roughly 85% of all cancer cases worldwide. It is predicted that the number of cancer cases will increase in the near future due to cigarette smoke, which contains at least 73 known carcinogens.
- Increased environmental pollution control measures are encouraged by the serious factor of the growth in environmental pollution. However, people who are exposed to high levels of pollution for a longer period of time are more likely to develop cancer.
- The advancement in cancer case detection has made it simpler than ever to administer lung cancer treatments like chemotherapy and surgery, which will accelerate the growth of the market for these treatments over the course of the forecast period.
- The industry for lung cancer therapeutics is expected to benefit from the expansion and inclusion of cancer-related treatment and care by a number of insurance providers during the expected period.
Lung Cancer Therapeutics Market Restraint
- The need for regulatory agencies with strict criteria and testing procedures to authorise treatments for lung cancer and other cancers could limit the market's expansion.
- According to estimates, the potential for growth would decline during the projection period due to the decreased life expectancy of patients undergoing lung cancer therapy constrained by the lack of lung organ transplants.
Request Free Customization of this report to help us to meet your business objectives.
Lung Cancer Therapeutics Market Competitive Landscape
The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market
Lung Cancer Therapeutics Market Top Player’s Company Profiles
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Novartis AG
- Astellas Pharma Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Millennium Pharmaceuticals, Inc. (Takeda)
- Merck Sharp & Dohme Corp.
- Eisai Co., Ltd.
- Johnson & Johnson
- Bayer AG
- GlaxoSmithKline plc
- Amgen Inc.
- Spectrum Pharmaceuticals, Inc.
Lung Cancer Therapeutics Market Recent Development
- In March 2022, AstraZeneca, PATH, and Qure.ai have teamed up to improve lung health in low- and middle-income countries. These three companies will collaborate to create a framework for using cutting-edge artificial intelligence technologies to detect lung cancer in patients undergoing chest screening for tuberculosis.
- In March 2022, Duke University has joined Known Medicine, a rapidly expanding biotechnology company that specializes in finding potent anticancer medications, to determine the efficacy of the drugs for patients with lung cancer. Through this agreement, Known Medicine will be able to evaluate and improve their ODINTM platform. Both parties want to assess the platform's ability to predict clinical outcomes accurately in about 75 patients.
Lung Cancer Therapeutics Key Market Trends
- One of the key reasons fueling the expansion of the global lung cancer therapeutic market in 2021 is the rising adoption and demand for targeted medicines, which are regarded as the cornerstone of precision medicine due to the rising R&D activities. According to estimates, among the several therapeutic kinds, targeted therapy has the biggest market share. Targeted therapy held a market share of 51.1% and is expected to grow over the course of the forecast period. The expansion of the targeted therapy market is also being driven by a growing emphasis on lung cancer detection and subsequent treatment based on precise targeting of the tumour or cancer source.
- During the projection period, the immunotherapy segment is expected to expand at a quicker CAGR. This is due to the rise in new product introductions, particularly in the immunotherapy market. Due to its better success in terms of effective treatment resulting to improved patient outcomes, immunotherapy is currently being used more widely in the markets in developed countries. This is expected to contribute to the market's expansion at a higher CAGRS during the forecast period.
Lung Cancer Therapeutics Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
According to our analysis, the Increasing Use Target therapy segment dominated the global Lung Cancer Therapeutics Market in 2021 and is expected to maintain its dominance throughout the forecast period. In 2021, North America dominated the global lung cancer therapeutics market owing to the region's increase in hospitals and rising R&D activities.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 32.2 billion |
| Market size value in 2031 | USD 86.8 billion |
| Growth Rate | 13.2% |
| Base year | 2023 |
| Forecast period | 2024–2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Lung Cancer Therapeutics Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Lung Cancer Therapeutics Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Lung Cancer Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Lung Cancer Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Lung Cancer Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Lung Cancer Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
